Empowering COPD patients – patient-centric solutions to drive positive outcomes
COPD is a widespread, costly and largely preventable condition which affects over 300 million people worldwide and is recognised as the ‘third-leading’ cause of death in most countries. Adherence rates among patients with the condition are seen to be low, despite evidence that shows appropriate use of medication and sensible lifestyle changes can reduce mortality by 60% and hospital admissions by as much as 42%.
Given the proven increase in quality of life when adherence occurs, and yet the persistence of non-adherence globally, there is clearly a disconnect. So why is poor self-management so prevalent and what can we do about it?
In conjunction with self-management and behavioural change specialists Atlantis Healthcare, we present a multi-stakeholder webinar and debate, which will combine real world patient needs with expertise from healthcare, pharma and patient advocates to look at the challenges to successful self-management/adherence and ascertain what the industry can do to better support patients in achieving optimum outcomes.
The webinar is comprised of 15 minutes of presentation and 40 minutes of live debate - which you can participate in, sending questions to the panel.
A live tweetchat (#rwCOPD) will follow the webinar, enabling full interaction across all stakeholders to further delve into this topic and explore some of the issues and solutions raised during the webcast.
This is the second webinar within the Patient Insights Summarized series.
Your panel for this event is:
Ana-maria Arboleda, Managing Director, Atlantis Healthcare Spain
Dr Joan Escarrabill, Director of the Master Plan for Respiratory Diseases, Ministry of Health (Catalonia)
Prof. John Weinman, Head of Health Psychology, Atlantis Healthcare
Rolf Taylor, Senior Director, Corporate Development, COPD Foundation
Paul Tunnah (Moderator), CEO, pharmaphorum
RecordedFeb 4 201564 mins
Your place is confirmed, we'll send you email reminders
Roberto Slepetys, Martin Pöhlchen, Gayatri Gopal, Andrew McConaghie
With rising healthcare costs, more informed and engaged patients, and advancing technology, health wearables have seen a significant uptake in recent years. However, the full potential of health wearables has yet to be recognised and there are still challenges to be resolved. What needs to be done on the regulatory, technical and healthcare side to take health wearables to the next level?
In this webinar, experts from the life sciences and technology industries discuss their views on the current state and future developments of health wearables, including:
– The user perspective: perception, adoption and expectations today and tomorrow
– The technology perspective: biggest successes and most room for improvements
– The societal and regulatory perspective: cost and risks versus benefits and opportunities
Working with QuintilesIMS, we present a digital debate which will offer modellling-based insights into the future of hepatitis C treatment.
Key topics to be discussed include:
– The burden of HCV
– The current market landscape
– The current patient access model and its impact on budget
– Cost efficiencies shown by modelling
– Cure versus lifetime treatment costs
Over the past 20 years, behavioural economics has identified factors that influence and determine how people behave, including alternative decision-making pathways and many cognitive biases and heuristics. Taking account of these helps to build a clear view of how healthcare customers think and behave in relation to your product in the real world.
This short masterclass explores ‘quantitative demand assessment research’ – what it is and how insights from behavioural economics can improve the application of this important tool in pharmaceutical market research.
The masterclass will:
•Introduce demand assessment research and why it is important to healthcare market research
•Discuss how insights from behavioural economics can improve quantitative demand assessment market research
•Highlight a range of techniques using behavioural economics that help you build a more accurate picture of your customers and market.
Video content accounted for 64% of all the world’s internet traffic in 2014 and is expected to grow to 80% by 2019. As the way in which we connect and digest information evolves, high quality mobile video capture and advanced digital analysis offers ever more authentic, intimate and rich insights into the customers’ world. This webinar will focus on:
– How emerging technology can enable us to realise the true value of ‘video data’ in our analysis and beyond
– How mobile technology can be used to get you closer to your customers and their real world experiences right from the earliest stages in product development
– How real world video content can engage your key stakeholders and ensure customer insights drive action
John Grumitt, IDF/Diabetes UK, Prof Michael Trenell, Newcastle University, Dr Phil McEwan
Diabetes is one of the most prevalent and most costly conditions worldwide – with a prevalence equating to 8.5% of the global population. Due to the complex nature of diabetes, with numerous co-morbidities and its asymptomatic nature, accurately modelling and therefore discerning which interventions are most effective, in terms of cost and patient impact is an equally complicated process.
This webinar will explore the patient pathway and how effective modelling – when pharma works together with healthcare stakeholders – can improve outcomes for both patients and the healthcare system as a whole.
Malcolm Qualie, NHS England, Nina Pinwill, NICE, Katie Pascoe, ABPI, Angela McFarlane, IMS Health Toby Gosden, IMS Health
Join us for a one-hour live debate on Cancer Treatment Access: Right Strategy, Right Approach, Right Outcomes.
To ensure funding and patient access to innovative cancer therapies, industry now have to navigate a new English cancer-treatment funding ecosystem, engaging with NICE and NHS England to realise a yes, no or conditional arrangement.
How can oncology treatments achieve a positive NICE appraisal in the new world and what will the mechanics of RWE be in the event of conditional funding via the reformed cancer drugs fund?
John Smith, PAGB, Rob Darracott, Pharmacy Voice, Sandra Gidley, English Pharmacy Board
New measures proposed by the Government will impact community pharmacies across the UK; the biggest change of this nature in decades. The impact will go beyond community pharmacies as other stakeholders also feel the pressure.
UK pharmacies already support more inhabitants per pharmacy than other major European markets; how will this funding change impact how patients are cared for in the community? How will pharmacy suppliers, such as consumer health companies, operate in the increasingly cost constrained and competitive environment?
Working with our partner, IMS Health, we present an interactive webinar to share market insight on the potential impact and a live discussion with critical stakeholders of this change. Hear directly from key stakeholders about their thoughts of how the changes will play out, and what this means for you in your sector.
Stephen Dorrell, Chair NHS Confederation, Leslie Galloway, EMIG, Prof. Mike Bewick, prev NHS England, Dr Rick Greville, ABPI
The pharmaceutical industry is one of the largest contributing industries to the UK’s balance of trade, and the UK Nation Health Service (NHS) is the fifth largest employer in the world.
Although the process of exit for the UK from the EU has now to be triggered by invoking article 50, the post-Brexit calendar is a firestorm of uncertainty. The uncertainty could potentially have a chilling effect on global pharma investment in the UK, but are the issues that will impact Pharma - a jewel in the crown of UKPLC - being heard in Westminster - and Brussels?
In order to better understand the potential impact of Brexit on both pharma and healthcare in the UK, we are working with specialist IMS Health to bring a unique debate in which a hand-picked panel of experts will discuss and analyse:
The impact of Brexit on UK Healthcare
The ramification of Brexit for pharma in the UK
What does the Brexit scenario mean for global pharma?
Alexandre Gultzgoff, Deputy Director, IT, Sanofi Pasteur MSD Antoine Blanc, Commercial Excellence Director, Sanofi Pasteur MS
Sanofi Pasteur MSD is transforming its commercial organisation and remodeling its approach to customer engagement. Hear from Sanofi Pasteur MSD’s Alexandre Gultzgoff, Deputy Director, IT, and Antoine Blanc, Commercial Excellence Director, as they share first hand insights on how they are transforming their European commercial operations and improving customer engagement. Learn from their best practice as they share Sanofi Pasteur MSD’s:
· Vision and strategy for digital transformation
· Digital channels (CLM, email) to improve customer engagement
· Deployment of a digital supply chain in ensuring fresh content to channels and content reuse
Jo Fearnhead-Wymbs, Ashfield Healthcare, Anita Osborn, Ashfield Clinical, Andrew Schorr, Patient Power, Paul Robinson, MS
This webinar will delve into the challenges that pharma face when looking at their patient-centricity strategy, and the opportunities that exist with this approach. We will explore the key motivators for this approach, and steps to overcome the internal and external barriers, and most importantly – how do pharma companies know when they have become truly patient-centric? How should they measure the impact of their strategy through the lifecycle of a drug and their business as a whole?
Blake Morrison; Harleen Parmar; Seth Whitelaw; Paul Tunnah
In today’s competitive, highly regulated environment, product success is dependent upon data and fact-based decision making. More and more, Medical Affairs teams play a pivotal role in education pre- and post-launch, yet the explosion of big data in healthcare is changing how we make value-based decisions that are critical to success.
This webinar will explore the challenges Medical Affairs teams have finding a repeatable, objective and compliant solution to identify and manage their strategic programs.
With a wealth of information available, it can be difficult to sort through data and understand what is important to incorporate into research and strategy. In this session you’ll hear needs and use cases for having a robust data strategy when it comes to Medical Affairs success. The panelists will share best practices for making fact-based decisions that meet compliance restrictions, using powerful market insights gained from multiple data sources, to optimize strategic planning and ultimately drive product success.
Paul Tunnah, Dr Mike Thompson, Dr Richard Simcock, Silja Chouquet, Andrew Schorr
The ASCO Annual Meeting, the largest global oncology meeting and increasingly the centre of a kaleidoscope of social media coverage each year.
As a snapshot, 2014 saw 40,000 tweets and 140m+ impressions over the conference days, 2015 grew to 60,000 tweets and 250m+ impressions and the 2016 buzz is already louder and more plentiful than last year.
This webinar will examine the conversation around ASCO 2016, its relationship with ASCO, value to and involvement from stakeholder groups and how it will potentially continue to evolve into 2017.
Athula Herath (Novartis), Umang Patel (Babylon Health), Peter Emberson (UK Pharma IT Forum), Paul Tunnah (pharmaphorum)
A unique Q&A session/open forum panel debate.
It is likely that you interact with ‘the cloud’ on various devices, multiple times throughout the day. However, for pharma we have only just scratched the surface regarding what the cloud can offer in terms of security, connectivity and efficacy. ‘Business analytics’ and ‘cloud’ are often misunderstood.
To answer this, pharmaphorum, in conjunction with industry stalwarts Equinix, present a unique Q&A event, offering the opportunity to ask any questions you may have around what the cloud can do, and how to remain compliant in utilising this technology.
This debate is an open forum and the expert panel will offer insight about interaction between the cloud and pharma with a particular focus on:
• Patient outcomes – The cloud and patients, what are the routes to improving outcomes?
• Internet of things – As the ways to gather data and interact increase exponentially, how does the cloud support this? What are the opportunities and can we eliminate the risk?
• Data and security – How to achieve compliance almost automatically.
• Collaboration – Why and how the cloud enables true partnership working.
David Davidovic, Jerome Mead, Leilani Latimer, Paul Tunnah
There are clear benefits for both Life Sciences companies and their customers in significantly improving the way they engage. Be it in terms of reputation, efficiency, profitability, or even relationship quality and longevity, engagement has and will always be the key to successful business practice.
Recent exclusive research conducted in conjunction with Zephyr Health revealed that both frontline sales forces and sales management professionals want to improve engagement strategies with new technology utilizing predictive insights. However, despite having new tools available to them, sales teams remain heavily reliant on the same techniques that were being used decades ago.
So what is the answer – how do life sciences companies disrupt this pattern and make significant strides to improve engagement?
Working with Zephyr Health, we present an expert webinar that will answer this very question, bringing together industry experts to discuss why the disruption is critical, how it can be achieved, and the core role that predictive insights play in this process.
As with all of our webcasts, this is an interactive debate designed to enable you to get the answers you need.
Topics covered include:
•Customer engagement challenges and trends: the need for disruptive customer engagement – what the survey revealed
•The challenges facing Life Sciences customer engagement
•Why technology is only partially solving the problem
•The evolution of CRM: from historic analytics to current analytics to future analytics – knowing what your customer wants before they do
•Overcoming internal blockers to change within Life Sciences – the roadmap for success
Kai Gait, Maneesh Juneja, Lions Health jury member, Paul Tunnah
Meeting the needs of both patients, and healthcare professionals, in today's fast changing communications landscape can be challenging, particularly against the backdrop of compliance. Putting creativity at the heart of the process can be the most effective way of tackling these challenges.
Although the return on investment of creativity is not always easy to measure, the value it can bring to pharma and healthcare is increasingly evident.
This webinar brings together a wealth of expertise to deliver case-study based evidence, interactive debate and practical advice on deriving competitive advantage from the creative process and ensuring patients are truly at the heart of your business.
Andrew Bromley (SDL); Chris McCourt (SDL); Paul Mitchel (Acurian)
According to the European Commission and NIHR Clinical Research Network, between 2007 and 2011, delays for launching clinical trials rose by 90%. And with approximately one third of the clinical trial timeline spent in patient recruitment, delays in launching clinical trials will increase costs and drain resources.
As our industry moves to become fully and demonstrably patient centric, there is much focus on the materials and media which are often the key liaison with the patient populous. As important as what we are saying and where these conversations are taking place may be, it is only part of the conundrum. Developing, maintaining and managing content is a continuous challenge, made all the more taxing not only by strict internal deadlines but the cultural, linguistic and regulatory challenges that go hand in hand with managing global communications.
Working with our expert partner SDL , we present a live webinar which will deliver insight and guidance on this topic, look in depth at one of the more traditional areas of patient liaison – trial recruitment – and bring you advice from the ‘frontline’ on what works in tackling these content challenges.
On this latest live webinar, we’ll be discussing:
•How to develop patient-centric recruitment content that REALLY communicates
•Best practices of how to handle the linguistic, cultural and regulatory challenges often faced with creating multilingual patient-centric content
•How simple content management best practices can help you become more patient centric with your content
•Recent case studies: we’ll be discussing recent successes of global pharmaceutical businesses that have optimised and streamlined recruitment processes with relevant, accurate content development in the right language.
The first in a trilogy of webinars focussed on the topic; Unlocking the value; the economic equation and part of the IMS Health Practical Insights series.
While it remains the gold standard, the feasibility of large scale randomised clinical trials within a pipeline that is ever more focused on niche and personalised medicines is decreasing – particularly in the fields of rare diseases and oncology. Within the changing landscape of drug development, payers need robust evidence in order to accurately assess the value and efficacy of innovative treatments for both smaller patient populations and increasingly expensive medicines. Answering this paradigm is where real world evidence can step in.
Topics covered include:
•The HTA landscape – the challenges of assessing rare disease and cancer medicines
•How regulators consider RWE in HTAs
•Learnings from best practice in global markets
•Recent case studies – successes and failures
•The role of the regulator in the Cancer Drugs Fund
•How RWE can assist market access
The current market research climate in the pharmaceutical industry is one of “doing more with less”. At the same time the number of healthcare professionals engaging with market research is on the decline.
So how do marketing teams cope with these two challenges and continue to produce good business intelligence for big brand decisions? Cello Health Insight’s quantitative team, IQ, argues that this is an ideal environment in which to start making greater use of advanced analytics techniques to make data work harder delivering insights which enable those teams to make market leading competitive decisions.
This webinar is designed to be an introduction to the potential of advanced analytics and will give practical learnings on how advanced analytics can:
• Help you optimise your communications channel mix to reach the greatest number of customers with the least possible resource commitment
• Give you the outputs and insights that provide clear prioritisation between options that are being weighed up for a marketing plan (e.g. visual concepts, messages) and help you make an optimum decision for your brand to drive product success
• Reveal the mindspace of your customers, visual insights into how patients and physicians think about your brand vs. your competitors’, whether you really are differentiated in the market, and alternatively what white space exists in the market that your brand could successfully occupy
Tim Ringrose, CEO M3 EU; Paul Mannu, Behavioural Insights Specialist, Cello Health Insight & Paul Tunnah, CEO, Pharmaphorum
So, we are finally at a point where with some certainty we can confirm we are in a digital world (this may have been true for some years in most industries – but is certainly truer in healthcare than ever before)… which means in terms of innovation within sales, within marketing, even within communicating effectively – digital is at the heart of making things work better.
What does this mean for pharma, is our industry keeping pace, ahead of the curve or playing catch-up – what does this mean in terms of how pharma interacts with its customers, particularly doctors – who are ever more connected digitally with their customers – patients…. What do they need?
This webinar brings together three leading industry experts – who will discuss, present practical insight and debate on the following topics:
1. Innovate or fail - the reality of engagement in a digital world
2. How is the doctor patient relationship changing in the evolving digital healthcare environment?
3. Why physicians need pharma to be more innovative in its communications.
4. The three tenets of digital: differentiation, intervention and communication
Andrew McConaghie, pharmaphorum; Stuart Turnham, Equinix; Jon Gunne, FFW
Digital – a word which is ubiquitous within our industry now and no longer the exclusive domain of IT or marketing. It should not be seen as simply an enabler; intelligent and progressive digitisation is now a fundamental business need in all areas of pharma and healthcare.
We present an exclusive webinar with global data centre and interconnectivity specialist Equinix, joined by digital and technology experts FFW and moderated by our own Paul Tunnah. This debate will provide practical insight and delve deep into the challenges at hand in managing the digitisation of our industry.
Topics covered will include:
•Why being digital is no longer an IT function but rather a business need – analysis and insight into the current market and the coming 3 to 5 years
•Managing data – how pharma needs to change its IT foundations to remain commercially optimised in a changing healthcare environment, including the move from pill to patient
•How industry can prepare – why connected is not enough – definition and benefits of interconnectivity, with learnings from the financial sector
Thought leadership webinars within the pharmaceutical industry
pharmaphorum provides a digital podium for communicating thought leadership and innovation within pharma. Our webinars bring together different stakeholders from across the healthcare spectrum to drive fresh thinking and novel solutions that deliver better outcomes for patients.